Abstract:Alzheimer's disease (AD) is the leading cause of dementia, afflicting 5 million Americans and costing over 200 billion dollars per year. The mechanisms involved in AD pathogenesis are still poorly understood. Moreover, no therapy is available to cure AD or to slow down its progression. The study of new pathways involved in AD pathogenesis is necessary to develop new therapeutic targets. The 12/15-lipoxygenase enzymatic pathway (12/15-LO) is upregulated in postmortem brain tissues and cerebrospinal fluid of AD patients. Its genetic absence or pharmacological inhibition prevents the development of the AD-like phenotype in transgenic mouse models of the disease. However, whether targeting pharmacologically this pathway after the neuropathological lesions and behavioral impairments are well established could be a viable therapeutic strategy against AD remain to be investigated. To this end, 12-month-old triple transgenic mice (3xTg) and their appropriate wild type controls were randomized to receive a specific and selective pharmacological inhibitor of 12/15-LO, PD146176, or placebo. After 3 months, when the animals were 15-month-old, treated and untreated groups were assessed for the effects of the drug on their behavioral impairments and neuropathology. While 15-month-old 3xTg mice on placebo by the end of the study showed a worsening of their memory and learning abilities, as assessed by the fear conditioning paradigms, mice at the same age receiving the PD146176 performed better than baseline in the same test. Compared with placebo, treated mice had significantly less Abeta levels and deposition, improved tau pathology as well as markers of synaptic integrity. Additionally, the same PD146176 treated animals showed a significant upregulation of autophagy markers, suggesting an involvement of this pathway in the pharmacological effect. In vitro experiments demonstrated that 12/15-LO effect on tau metabolism is mediated by modulating neuronal autophagy system. These studies provide new insights into the disease-modifying action of pharmacological inhibiting 12/15-LO as a viable therapeutic approach for AD treatment. They represent the successful completion of the preclinical studies for the development of this class of drug as clinically applicable therapy for the disease.

Targeting USP11 regulation by a novel lithium-organic coordination compound improves neuropathologies and cognitive functions in Alzheimer transgenic mice

A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

Beneficial effects of tri-lithium pyrroloquinoline quinonein on behaviors and pathology in a mouse model of Alzheimer’s disease

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

RETRACTED ARTICLE:LISPRO Mitigates Β -Amyloid and Associated Pathologies in Alzheimer’s Mice

Beneficial Synergistic Effects of Microdose Lithium with Pyrroloquinoline Quinone in an Alzheimer's Disease Mouse Model

Combination of RNA-seq and proteomics reveals the mechanism of DL0410 treatment in APP/PS1 transgenic mouse model of Alzheimer's disease

Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer's disease.

DL0410 ameliorates cognitive disorder in SAMP8 mice by promoting mitochondrial dynamics and the NMDAR-CREB-BDNF pathway

Systemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy

Design, synthesis and biological evaluation of novel pyrazolinone derivatives as multifunctional ligands for the treatment of Alzheimer's disease

12/15-LIPOXYGENASE INHIBITION REVERSES COGNITIVE IMPAIRMENT, AMYLOIDOSIS, TAU AND SYNAPTIC PATHOLOGY BY STIMULATING AUTOPHAGY IN THE BRAIN OF AGED 3XTG MICE

Cognition-enhancing effect of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in the 5 x FAD transgenic mouse model of Alzheimer's pathology

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo

P1‐017: 12/15‐lipoxygenase Inhibition Reverses Cognitive Impairment, Amyloidosis, TAU and Synaptic Pathology by Stimulating Autophagy in the Brain of Aged 3XTG Mice

Selective Degradation of Hyperphosphorylated Tau by Proteolysis-Targeting Chimeras Ameliorates Cognitive Function in Alzheimer’s Disease Model Mice

A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models

A potent phosphodiester Keap1-Nrf2 protein-protein interaction inhibitor as the efficient treatment of Alzheimer's disease

A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment

Neuroinflammation inhibition by small-molecule targeting USP7 noncatalytic domain for neurodegenerative disease therapy

Design, Synthesis, and Pharmacological Characterization of Sulfonylurea-Based NLRP3 Inhibitors: Towards an Effective Therapeutic Strategy for Alzheimer's Disease